1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Incyte’s Oral JAK1 Inhibitor Shows Potential In Facial, Full Body Vitiligo

 
• By Joseph Haas

After promising Phase IIb 24-week data with povorcitinib, Incyte unveiled 52-week data indicating greater improvement with longer-term therapy and plans to initiate a Phase III trial.

Vitiligo
Incyte is hoping to bring vitiligo patients multiple therapeutic options • Source: Shutterstock

Incyte Corporation is making progress toward providing vitiligo patients with therapeutic options, as it presented Phase IIb data on 11 October at the European Academy of Dermatology and Venereology Congress showing that oral selective JAK1 inhibitor povorcitinib at multiple doses can improve facial or full-body depigmentation in patients with nonsegmental vitiligo.

The company already offers Opzelura (ruxolitinib), a topical formulation of the active ingredient in its JAK1/2 inhibitor Jakafi, as a therapy for vitiligo and atopic dermatitis. (Also see "Incyte Bolsters Dermatology Ambitions With Vitiligo Approval For Topical Ruxolitinib" - Scrip, 19 July, 2022

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.